Table 3.
Risk of venous thrombosis associated with different types of progestogens in combined oral preparations. Data are numbers (percentages) unless stated otherwise
| Type of progestogen | Thrombosis patients (n=1524) | Controls (n=1760) | Odds ratio (95% CI)* |
|---|---|---|---|
| Levonorgestrel† | 485 (31.9) | 373 (21.2) | 3.6 (2.9 to 4.6) |
| Gestodene† | 119 (7.8) | 67 (3.8) | 5.6 (3.7 to 8.4) |
| Desogestrel† | 289 (19.0) | 108 (6.2) | 7.3 (5.3 to 10.0) |
| Lynestrenol† | 44 (2.9) | 19 (1.1) | 5.6 (3.0 to 10.2) |
| Norethisterone | 11 (0.7) | 7 (0.4) | 3.9 (1.4 to 10.6) |
| Cyproterone acetate | 125 (8.2) | 62 (3.5) | 6.8 (4.7 to 10.0) |
| Norgestimate | 9 (0.6) | 4 (0.2) | 5.9 (1.7 to 21.0) |
| Drospirenone | 19 (1.2) | 14 (0.8) | 6.3 (2.9 to 13.7) |
| No oral contraceptive (reference) | 421 (27.7) | 1102 (62.8) | 1 |
*Odds ratio adjusted for age and period of inclusion (categorical; divided per 6 calendar months).
†Analysis restricted to preparation with most commonly used dose of oestrogen: for levonorgestrel, gestodene, and desogestrel, 30 μg (645 patients and 385 controls); for lynestrenol 37.5 μg (42 patients and 19 controls).